PZKKN-94
PZKKN-94 is a dual serotonin 5-HT1B receptor agonist and serotonin 5-HT6 receptor antagonist which is under investigation for the potential treatment of Parkinson's disease. Its values were 39nM and 88.1% at the serotonin 5-HT1B receptor and 7.7nM at the serotonin 5-HT6 receptor. The drug showed selectivity for these receptors over 43other targets. It shows favorable drug-like properties. In rodents, PZKKN-94 shows antiparkinsonian-like, pro-cognitive, and antidepressant-like effects. PZKNN-94 was first described in the scientific literature by Paweł Zajdel and colleagues in 2025.